Abstract:Sonogenetics is a promising approach for in vivo neuromodulation using ultrasound (US) to non-invasively stimulate cells in deep tissue. However, sonogenetics requires accurate transduction of US-responsive proteins into target cells. Here, we introduce a non-invasive and non-viral approach for intracerebral gene delivery. This approach utilizes temporary ultrasonic disruption of the blood-brain barrier (BBB) to transfect neurons at specific sites in the brain via DNA that encodes engineered US-responsive protein (murine Prestin (N7T, N308S))-loaded microbubbles (pPrestin-MBs). Prestin is a transmembrane protein that exists in the mammalian auditory system and functions as an electromechanical transducer. We further improved the US sensitivity of Prestin by introducing specific amino acid substitutions that frequently occur in sonar species into the mouse Prestin protein. We demonstrated this concept in mice using US with pPrestin-MBs to non-invasively modify and activate neurons within the brain for spatiotemporal neuromodulation. Method: MBs composed of cationic phospholipid and C3F8 loaded with mouse Prestin plasmid (pPrestin) via electrostatic interactions. The mean concentration and size of the pPrestin-MBs were (16.0 ± 0.2) × 109 MBs/mL and 1.1 ± 0.2 μm, respectively. SH-SY5Y neuron-like cells and C57BL mice were used in this study. We evaluated the gene transfection efficiency and BBB-opening region resulting from pPrestin-MBs with 1-MHz US (pressure = 0.1-0.5 MPa, cycle = 50-10000, pulse repetition frequency (PRF): 0.5-5 Hz, sonication time = 60 s) using green fluorescence protein (Venus) and Evans blue staining. Results: The maximum pPrestin expression with the highest cell viability occurred at a pressure of 0.5 MPa, cycle number of 5000, and PRF of 1 Hz. The cellular transfection rate with pPrestin-MBs and US was 20.2 ± 2.5%, which was 1.5-fold higher than that of commercial transfection agents (LT-1). In vivo data suggested that the most profound expression of pPrestin occurred at 2 days after performing pPrestin-MBs with US (0.5 MPa, 240 s sonication time). In addition, no server erythrocyte extravasations and apoptosis cells were observed at US-sonicated region. We further found that with 0.5-MHz US stimulation, cells with Prestin expression were 6-fold more likely to exhibit c-Fos staining than cells without Prestin expression. Conclusion: Successful activation of Prestin-expressing neurons suggests that this technology provides non-invasive and spatially precise selective modulation of one or multiple specific brain regions.

Sonogenetic-Based Neuromodulation for the Amelioration of Parkinson’s Disease

An Antisense Oligonucleotide-Loaded Blood–Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson’s Disease

A Preliminary Study of Parkinson's Gene Therapy Via Sono-Magnetic Sensing Gene Vector for Conquering Extra/intracellular Barriers in Mice

Targeted Delivery of Engineered Auditory Sensing Protein for Ultrasound Neuromodulation in the Brain

Noninvasive Ultrasound Deep Brain Stimulation for the Treatment of Parkinson’s Disease Model Mouse

Holographic Ultrasound Modulates Neural Activity in a 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Mouse Model of Parkinson’s Disease

Piezoelectric Nanogenerators Enabled Neuromodulation Rescued Dopaminergic Neuron Loss in Parkinson’s Disease

Bioluminescence‐driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model

Enhanced De Novo Neurogenesis And Dopaininergic Neurogenesis In The Substantia Nigra Of 1-Methyl-4-Phyenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson'S Disease-Like Mice

Transcranial Ultrasound Stimulation Suppresses Neuroinflammation in a Chronic Mouse Model of Parkinson's Disease.

Ultrasonic stimulation of the brain to enhance the release of dopamine - A potential novel treatment for Parkinson's disease

Ultrasonic Stimulation of the Brain to Enhance the Release of Dopamine - A Potential Novel Treatment for Parkinsons Disease

An upconversion nanoplatform based multi-effective theatment for Parkinson’s disease

Modulation of deep neural circuits with sonogenetics

Wearable Ultrasound Improves Motor Function in an MPTP Mouse Model of Parkinson's Disease

An Upconversion Nanoplatform Based Multi-Effective Theatment for Parkinson's Disease

Ultrasound targeted CNS gene delivery for Parkinson's disease treatment

Vagus nerve stimulation with a small total charge transfer improves motor behavior and reduces neuroinflammation in a mouse model of Parkinson's disease

Synergetic Therapeutic Efficacy of Fasudil and Bone Marrow Derived-Neuronal Stem Cell in a Parkinson's Disease Mouse Model

Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier

Sonogenetic modulation of cellular activities using an engineered auditory-sensing protein